Guidelines & Review Panels
The AMCP eDossier System is a centralized, secure, web-based platform, that provides qualified health care decision makers the opportunity to easily access, review, and evaluate research to make informed, evidence-based decisions.
A Format for Submission of Clinical and Economic Evidence of Pharmaceuticals in Support of Formulary Consideration. FMCP Format Executive Committee. (Source: Journal of Managed Care Pharmacy, Jan. 2010)
Six Blue Cross plans have joined to collaborate on providing online access to a health care cost information tool called "Care Comparison". Organizers of the effort say the easy-to-access, online tool, will serve more than 48 million consumers who will have access to cost information. (Source: Managed Care Information Center, Nov. 17, 2009)
This creates a decision framework for "best evidence" approaches in systematic reviews. This will be Phase I of a larger project (Phase II would involve a formal evaluation of the impact of variations in inclusion criteria on a review's conclusions).
Aim of this editorial by Turk is to discuss the results of a study reviewing the positions of various national guidelines in relation to the transferability and generalizability of data and the methods suggested for addressing issues of transferability presented in this issue. Source:Value in Health.
This includes HTA, CEA, and discussion of barriers for Asia as a whole, Thailand, Taiwan, Uganda, Latin America and Caribbean, and low- and middle-income countries. (Source: Pharmaeconomics, Nov. 1. 2009)
ISPOR Connections discusses perspectives on the use and value of health economics from a governmental perspective from the UK, Germany, Sweden, Spain, The Netherlands. (Source: Mittendorf, ISPOR Connections, Nov/Dec. 2009, p.15)
Tool developed specifically for managed care professionals to address their unique needs. This is a site which can help you track late-phase pipeline including in-depth reviews, tabulated format for a quick analysis, search and filtering capabilities, default and customized reports, and frequent updates
The aim of this study was to explore the current status of EBM among different medical specialists in Iran. This cross-sectional study was conducted from August 2007 until March 2009 on a sample of 181 doctors in different medical specialties practising in Isfahan, Iran, not including faculty members.(Source:Mozafarpour S, et.al,January 30, 2011, Journal of Evaluation in Clinical Practice)
Article by Hughes DA in Br J Clin Pharmacol Sep 2010
From 2011 onwards new medicines will have to undergo a benefit assessment. The GBA will commission this to IQWIG or other third parties. Prices can be freely set for the first six month, if no additional benefit can be demonstrated the drug will thereafter automatically be part of the therapeutic reference price system. If an additional therapeutic benefit is established manufacturers will negotiate prices with the statutory health insurance funds, if no agreement can be reached prices will be fixed by an independent arbitrary commission taking into consideration the EU price level.(Source: Health Economics Blog)
This is the third and last article in the series about the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to grading the quality of evidence and the strength of recommendations in clinical practice guidelines and its application in the field of allergy.(Source: Pubmed, Brozek, JL et. al.)
Full list of available quality of care reports, EBM guides, etc.
The caliber and stature of this group is a testament to the importance of addressing issues of effectiveness and quality in the healthcare delivered across New England,' stated Steven D. Pearson, MD, MSc, President of ICER. 'We look forward to working with this distinguished council to produce actionable, relevant information for patients, providers and policymakers in New England.'"
This publication presents overviews of the health care systems of 13 countries—Australia, Canada, Denmark, England, France, Germany, Italy, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United States. A summary table presents information on population, health care spending, number of physicians, hospital spending and utilization, use of health information technology, and number of potentially avoidable deaths.
This report presents the 'gold standard' to which those who conduct systematic reviews should aspire to achieve the most reliable and useful products,' said Alfred O. Berg, MD...'We recognize that it will take an investment of resources and time to achieve such high standards, but they should be adopted to minimize the chances that important health decisions are based on information that may be biased or erroneous,' Berg said."
The Institute of Medicine (IOM) released a new report outlining its recommended standards for systematic reviews of the comparative effectiveness of medical or surgical interventions (see the list of the standards). In developing its standards, the IOM relied on the current methodological evidence and guidance from respected organizations that produce systematic reviews.
The Swedish authority for registration of new drugs. Like FDA but in Sweden.
Products are developed and supported by healthcare professionals with extensive Medicaid experience. More than 1,900 clients use the Care Guidelines®, including managed Medicaid plans, state Medicaid plans and Quality Improvement Organizations. The Care Guidelines® address many of the healthcare issues seen among Medicaid populations
The guidelines manual has been updated following public consultation. The manual explains how NICE develops clinical guidelines and provides advice on the technical aspects of guideline development (Source: NICE).
The National Institute for Health and Clinical Excellence (NICE) will have existed for 10 years on April 1, 2009.(Source: The Lancet Oncology, Volume 10, Issue 4, Pages 417 - 424, April 2009)
The existing roles and responsibilities of NICE are however expected to remain unchanged. Rawlins was not so forthcoming on one issue of particular interest to the pharmaceutical industry, however: value-based pricing. He claimed that NICE would play a critical role in developing such pricing for medicines in the U.K., but said the details of how this would work in practice have yet to be decided.
An online resource for P&T committee members in hospital-based and managed care organizations. Formkit provides P&T members with pharmacoeconomic information, FDA and industry news, and access to the most up-to-date formulary kits.
We provide external medical peer reviews and independent health care review services for government agencies and large health care providers, and help them control escalating health care costs while providing appropriate medical care.
Country-specific guidelines’ key features (32) as well as hyperlinks or full text of the guideline (as copyright permission allows) or publication reference including a map of the country
The PE guidelines are government regulatory documents, publications, or suggested guidances or best practices for conducting PE or outcomes research and use of this information in health care decisions and reimbursement decisions.
Jeff Waite, on behalf of pharmaphorum, caught up with health economist Leela Barham, to discuss not only the ways in which the public and patients can engage with NICE, but why such discussions are in fact pivotal to an effective use of finite financial resources. Having extensively reviewed relevant literature, and the NICE website, Leela discusses both formal and informal mechanisms that provide an opportunity for the public and patients to be involved. (Source: pharmaphorum, Jeff Waite)
Easy methods to weigh and understand the available evidence are indeed essential for readers and reviewers. The third updated and expanded edition of Systematic Reviews by the Centre for Reviews and Dissemination are now available.
Until now, Germany has been one of Europe's last bastions of "free" upfront drug pricing. Sure, the hurdles come afterwards, but both there and in the UK drug firms have--until now--been allowed to set more or less the price they like for new drugs. (Source: The IN VIVO Blog, March 8, 2010)
The European Medicines Agency has launched a three-month public consultation on its draft of The Road Map to 2015: The Agency's Contribution to Science, Medicines, Health with comments due by April 30, 2010. (Source: European Medicines Agency, Jan. 2010)
Delivers access to medical directors and pharmacy directors from payors for healthcare services companies, information technology providers, pharmaceutical manufacturers, and other companies offering products and services of interest to our advisors. TPG-NPRT provides interactive educational programs where decision makers meet.
HIQA has published new guidelines for the economic evaluation of health technologies in Ireland, which will standardise how evaluations are produced.The guidelines will apply to all healthcare treatments, including medications, procedures, medical devices and broader public health initiatives, and according to Dr Ryan, they are relevant to the assessment of both new and existing healthcare technologies.(Source:Irish Medical Times)
Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st century (Source:PharmacoEconomics, Volume 28, Number 10, 1 October 2010 , pp. 831-838(8), Author; Kamae, Isao1).
In December 2010, the Government launched its consultation on its plans to change the way medicines are priced in the UK. By 2014, a system of ‘value-based pricing’ (VBP) will replace the current Pharmaceutical Price Regulation Scheme (PPRS), which is a voluntary agreement between the Department of Health (DH) and the pharmaceutical industry whereby companies negotiate profit rates from drug sales to the National Health Service (NHS) every 5 years utilising price and profit controls.
